Allergy. 2019 Jan 12. doi: 10.1111/all.13718 |
AllergoOncology: microbiota in allergy and cancer - an EAACI position paper. |
Untersmayr E1, Bax HJ2, Bergmann C3, Bianchini R4, Cozen W5, Gould HJ6, Hartmann K7, Josephs DH8, Levi-Schaffer F9, Penichet ML10, O'Mahony L11, Poli A12, Redegeld F13, Roth-Walter F14, Turner MC15, Vangelista L16, Karagiannis SN17, Jensen-Jarolim E18 |
Abstract The microbiota can play important roles in the development of human immunity and the establishment of immune homeostasis. Lifestyle factors including diet, hygiene, and exposure to viruses or bacteria, and medical interventions with antibiotics or anti-ulcer medications, regulate phylogenetic variability and the quality of cross-talk between innate and adaptive immune cells via mucosal and skin epithelia. More recently, microbiota and their composition have been linked to protective effects for health. Imbalance, however, has been linked to immune-related diseases such as allergy and cancer, characterized by impaired, or exaggerated immune tolerance, respectively. In this AllergoOncology position paper, we focus on the increasing evidence defining the microbiota composition as a key determinant of immunity and immune tolerance, linked to the risk for development of allergic and malignant diseases. We discuss novel insights into the role of microbiota in disease and patient responses to treatments in cancer and in allergy. These may highlight opportunities to improve patient outcomes with medical interventions supported through a restored microbiome. This article is protected by copyright. All rights reserved. |
This article is protected by copyright. All rights reserved. |
KEYWORDS: AllergoOncology, Allergy, Breg, Treg, cancer, checkpoint, diet, lipocalin, hygiene hypothesis, immune tolerance, microbiome, microbiota |
Publikations ID: 30636005 Quelle: öffnen |